Streetbeat News

Stock Prices

NSPR

InspireMD presented one-year follow-up results from the C-GUARDIANS US IDE trial of CGuard at LINC 2024. The results were shared on May 28 at 8:53 a.m. EDT.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:56 pm

BNS

Scotiabank (NYSE:BNS) reported a 5.5% year-over-year revenue growth for Q2 fiscal 2024, beating consensus estimates. Despite a decline in adjusted EPS, the bank showed strong capital ratios and positive operating leverage. Shares are trading higher by 1.51% premarket.

Portfolio Pulse from Akanksha Bakshi

May 28, 2024 | 12:56 pm

SINT

Trading halt status for SINT was updated at 8:55:00 AM ET. The quotation resumption times and related news are expected to follow.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:55 pm

META

NVDA

SPY

Ed Yardeni, founder and CEO of Yardeni Research, has rebranded the 'Magnificent Seven' tech giants as the 'Magnificent One,' highlighting Nvidia Corp. (NASDAQ:NVDA) as the key driver of this year's market gains. Nvidia has surged 115% year-to-date, significantly outperforming other tech giants and the broader S&P 500 index. Yardeni attributes Nvidia's success to its dominance in the AI sector, though he cautions about the impact of high capital expenditures on its clients. Yardeni's 'Roaring 2020s' scenario predicts continued economic growth driven by technology, with the Dow Jones Industrial Average potentially reaching 60,000 points and the S&P 500 climbing to 8,000 by 2030.

Portfolio Pulse from Piero Cingari

May 28, 2024 | 12:52 pm

ABTC

BTCUSD

BTCW

CBTC

The first Bitcoin exchange-traded products (ETPs) have started trading on the London Stock Exchange, marking a significant milestone for cryptocurrency adoption in the U.K. Asset managers WisdomTree and 21Shares listed Bitcoin ETPs, including 21Shares Bitcoin ETN (ABTC), 21Shares Bitcoin Core ETN (CBTC), and WisdomTree Physical Bitcoin ETN (BTCW). These products are currently accessible only to professional investors under FCA regulations.

Portfolio Pulse from Benzinga Neuro

May 28, 2024 | 12:51 pm

APRE

Aprea Therapeutics' Safety Review Committee has endorsed dosing patients with ATRN-119 in the ABOYA-119 clinical trial. ATRN-119, a macrocyclic ATR inhibitor, has shown safety and tolerance through the first 5 cohorts with no dose-limiting toxicities. The company is on track to complete dose escalation and potentially generate initial human efficacy data in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:48 pm

AMD

AXP

MSFT

NVDA

SHEL

SPRX

STM

TRFK

AMD claims a 33% share in the server CPU market and is preparing to launch its next-gen 'Turin' processors. The company highlighted its growth in servers, CPUs, and GPUs, and announced partnerships with major companies like Microsoft. AMD's stock is trading higher, and analysts expect continued optimism in the semiconductor industry despite some challenges.

Portfolio Pulse from Anusuya Lahiri

May 28, 2024 | 12:48 pm

NRXP

NRx Pharmaceuticals presented its Phase 2b/3 trial results for NRX-101 at the ASCP Annual Meeting. The trial showed that NRX-101 significantly reduces suicidality and symptoms of akathisia in bipolar depression compared to the standard treatment, lurasidone.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:47 pm

IMCC

IM Cannabis Corp. (NASDAQ:IMCC) has announced the termination of a preliminary term sheet with Kadimastem Ltd. The company is focusing on maximizing shareholder value, especially with accelerated growth in Germany following legalization.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:46 pm

BITF

RIOT

Bitfarm shares are trading higher after Riot Platforms announced a proposal to acquire all outstanding shares of the company and accumulated a 9.25% stake.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:45 pm